Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.62 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.54 |
| ▸ | KIF11 | P52732 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216291 | 1.00 | PTGS2 (0.62) | PTGS2PTGS1CHRNA7CYP2C9CA12 | |
| SCHEMBL1123595 | 0.86 | KIF11 (0.51) | PTGS2PTGS1CYP2C9CA12CA1 | |
| SCHEMBL7212037 | 0.85 | PTGS2 (0.63) | PTGS2PTGS1CHRNA7CA12CA1 | |
| SCHEMBL7216202 | 0.84 | PTGS2 (0.59) | PTGS2PTGS1CHRNA7CYP2C9CA12 | |
| SCHEMBL2466828 | 0.83 | CHRNA7 (0.66) | PTGS2PTGS1CHRNA7CA12CA1 | |
| SCHEMBL5309196 | 0.83 | CHRNA7 (0.66) | PTGS2PTGS1CHRNA7CA12CA1 | |
| SCHEMBL1123613 | 0.83 | PTGS2 (0.60) | PTGS2PTGS1CHRNA7CYP2C9PDPK1 | |
| SCHEMBL1123783 | 0.83 | PTGS2 (0.61) | PTGS2PTGS1CYP2C9CA12CA1 | |
| SCHEMBL7210614 | 0.82 | PTGS2 (0.63) | PTGS2PTGS1CHRNA7CA12CA1 | |
| SCHEMBL7216347 | 0.81 | CHRNA7 (0.70) | PTGS2PTGS1CHRNA7CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196915-A1 | Antitumor 1,2-Diphenylpyrrole Compounds and their Preparation Process | ARGON PHARMA, S.L. (ES) | 2012-08-02 | — | — | US | disclosed |
| EP-2459532-A1 | ANTITUMOR 1,2-DIPHENYLPYRROLE COMPOUNDS AND THEIR PREPARATION PROCESS | Argon Pharma S.L. (ES) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011012660-A1 | ANTITUMOR 1,2-DIPHENYLPYRROLE COMPOUNDS AND THEIR PREPARATION PROCESS | ARGON PHARMA, S. L. (ES) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196915-A1 | Antitumor 1,2-Diphenylpyrrole Compounds and their Preparation Process | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TPD52L2, CYC1 | PTGS2 1289/4885PTGS1 1559/4885CHRNA7 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.